Jacobs R Jake, Saab Sammy, Meyerhoff Allen S
Capitol Outcomes Research, Alexandria, Virginia 22310, USA.
J Am Coll Health. 2003 May;51(6):227-36. doi: 10.1080/07448480309596355.
Hepatitis B immunization is recommended for all American children, and hepatitis A immunization is recommended for children who live in areas with elevated disease rates. Because hepatitis A and B occur most commonly in young adults, the authors examined the cost effectiveness of college-based vaccination. They developed epidemiologic models to consider infection risks and disease progression and then compared the cost of vaccination with economic, longevity, and quality of life benefits. Immunization of 100,000 students would prevent 1,403 acute cases of hepatitis A, 929 cases of hepatitis B, and 144 cases of chronic hepatitis B. Hepatitis B vaccination would cost the health system $7,600 per quality-adjusted life year (QALY) gained but would reduce societal costs by 6%. Hepatitis A/B vaccination would cost the health system dollar 8,500 per QALY but would reduce societal costs by 12%. Until childhood and adolescent vaccination can produce immune cohorts of young adults, college-based hepatitis immunization can reduce disease transmission in a cost-effective manner.
建议所有美国儿童接种乙肝疫苗,对于生活在疾病发病率较高地区的儿童,建议接种甲肝疫苗。由于甲型和乙型肝炎最常见于年轻人,作者研究了以大学为基础的疫苗接种的成本效益。他们建立了流行病学模型来考虑感染风险和疾病进展,然后将疫苗接种成本与经济、寿命和生活质量效益进行比较。对10万名学生进行免疫接种可预防1403例甲型肝炎急性病例、929例乙型肝炎病例和144例慢性乙型肝炎病例。乙肝疫苗接种每获得一个质量调整生命年(QALY)将使卫生系统花费7600美元,但可使社会成本降低6%。甲肝/乙肝联合疫苗接种每QALY将使卫生系统花费8500美元,但可使社会成本降低12%。在儿童和青少年疫苗接种能够产生免疫的年轻成人队列之前,以大学为基础的肝炎免疫接种可以以具有成本效益的方式减少疾病传播。